Printer Friendly

LECTEC REVIEWING POSSIBLE PATENT INFRINGEMENTS OF TRANSDERMAL NICOTINE TECHNOLOGY

 LECTEC REVIEWING POSSIBLE PATENT INFRINGEMENTS
 OF TRANSDERMAL NICOTINE TECHNOLOGY
 MINNETONKA, Minn., Dec. 24 /PRNewswire/ -- LecTec Corporation (NASDAQ: LECT) has requested its legal counsel to review possible infringement by major pharmaceutical companies concerning several of the company's basic transdermal patents. The decision by LecTec to review these patents was accelerated in light of recent legal activities concerning transdermal nicotine products.
 LecTec was granted patents during the early 1980s that provide for incorporation of cardioactives. This category includes nicotine.
 The company's patented transdermal technology is focused on passive diffusion of a drug carried by a monolithic membrane. LecTec recently announced investments into this segment of the company and new alliances to establish marketing partnerships with companies to distribute and sell LecTec-manufactured transdermal drug products.
 LecTec Corporation is a developer and manufacturer of transdermal drug delivery products, cardiac diagnostic and monitoring electrodes, and medical tapes. LecTec is publicly traded on NASDAQ under the symbol LECT.
 -0- 12/24/91
 /CONTACT: Jan Jachimowicz of LecTec, 612-933-2291/
 (LECT) CO: LecTec Corporation ST: Minnesota IN: MTC SU:


AL -- MN001 -- 5137 12/24/91 11:09 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 24, 1991
Words:180
Previous Article:CCA ISSUES $5 MILLION OF CONVERTIBLE PREFERRED STOCK
Next Article:CITICORP STATEMENT ON OFFICE OF THE COMPTROLLER OF THE CURRENCY ANNUAL EXAMINATION
Topics:


Related Articles
LECTEC BOARD APPROVES ADDED EMPHASIS ON TRANSDERMAL BUSINESS DEVELOPMENT; CITES SIGNIFICANT OPPORTUNITIES
ELAN: COURT REFUSES TO CONTINUE RESTRAINT AGAINST MARION MERRELL DOW
UNIMED, LECTEC TO PURSUE TRANSDERMAL DEVELOPMENT OF MARINOL
LECTEC BOARD INTENSIFIES FUNDING FOR TRANSDERMAL PATCH DEVELOPMENT; TO TREAT SMOKERS, CANCER PATIENTS, OTHERS
LECTEC TO LAUNCH NEW PRODUCT FOR TREATMENT OF BED SORES AND OTHER CHRONIC WOUNDS
ALZA, CYANAMID, ELAN AND MARION MERRELL CONCLUDE AGREEMENTS AND REACH AN OUT-OF-COURT SETTLEMENT
COURT RULES IN FAVOR OF CYGNUS MOTION FOR SUMMARY JUDGMENT; DISMISSES IMPORTANT PARTS OF PATENT INFRINGEMENT SUIT
CYGNUS SHIPS ITS NICOTINE PATCH
LECTEC AND UNIVERSITY OF MINNESOTA PURSUE SAFER ALTERNATIVE TO NICOTINE FOR SMOKING CESSATION PATCHES
CYGNUS REACHES SETTLEMENT WITH ELAN OVER NICOTINE PATCH SUIT

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters